Charles Schwab Investment Management Inc Summit Therapeutics Inc. Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,291,671 shares of SMMT stock, worth $24.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,291,671

Previous 1,460,717 11.57%

Holding current value

$24.2 Million

Previous $28.2 Million 2.45%

% of portfolio

0.0%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$16.64 - $36.7 $2.81 Million - $6.2 Million	-169,046 Reduced 11.57%	1,291,671 $27.5 Million
Q1 2025 Sep 15, 2025	BUY	$16.65 - $23.76 $2.81 Million - $4.02 Million	169,046 Added 13.09%	1,460,717 $28.2 Million
Q1 2025 May 09, 2025	SELL	$16.65 - $23.76 $405,510 - $578,674	-24,355 Reduced 1.64%	1,460,717 $28.2 Million
Q4 2024 Feb 06, 2025	BUY	$17.52 - $23.46 $917,329 - $1.23 Million	52,359 Added 3.65%	1,485,072 $26.5 Million
Q3 2024 Nov 12, 2024	BUY	$6.89 - $31.93 $3.43 Million - $15.9 Million	497,984 Added 53.28%	1,432,713 $31.4 Million
Q2 2024 Aug 12, 2024	SELL	$2.39 - $10.92 $195,540 - $893,430	-81,816 Reduced 8.05%	934,729 $7.29 Million
Q1 2024 May 08, 2024	BUY	$2.55 - $5.07 $159,882 - $317,883	62,699 Added 6.57%	1,016,545 $4.21 Million
Q4 2023 Feb 06, 2024	BUY	$1.67 - $2.83 $21,793 - $36,931	13,050 Added 1.39%	953,846 $2.49 Million
Q3 2023 Nov 08, 2023	BUY	$1.54 - $2.42 $969,778 - $1.52 Million	629,726 Added 202.44%	940,796 $1.76 Million
Q2 2023 Aug 09, 2023	BUY	$1.32 - $2.81 $391,365 - $833,134	296,489 Added 2033.39%	311,070 $780,000
Q1 2023 May 11, 2023	SELL	$1.38 - $5.41 $732 - $2,872	-531 Reduced 3.51%	14,581 $25,000
Q4 2022 Feb 13, 2023	BUY	$0.68 - $5.31 $10,276 - $80,244	15,112 New	15,112 $64,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.38 $56,407 - $145,924	-61,313 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.0 - $3.45 $12,560 - $21,666	6,280 Added 11.41%	61,313 $151,000
Q3 2021 Nov 16, 2021	BUY	$4.83 - $8.27 $35,669 - $61,073	7,385 Added 15.5%	55,033 $276,000
Q2 2021 Aug 16, 2021	BUY	$5.15 - $8.46 $245,387 - $403,102	47,648 New	47,648 $356,000

Others Institutions Holding SMMT

# of Institutions

270

Shares Held

90.8M

Call Options Held

4.71M

Put Options Held

3.17M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.76B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Summit Therapeutics Inc. Transaction History